POPULARITY
Categories
325 episodes with pharmd
158 episodes with pharmd
151 episodes with pharmd
165 episodes with pharmd
144 episodes with pharmd
168 episodes with pharmd
178 episodes with pharmd
126 episodes with pharmd
111 episodes with pharmd
73 episodes with pharmd
104 episodes with pharmd
93 episodes with pharmd
83 episodes with pharmd
93 episodes with pharmd
114 episodes with pharmd
55 episodes with pharmd
44 episodes with pharmd
47 episodes with pharmd
32 episodes with pharmd
40 episodes with pharmd
47 episodes with pharmd
31 episodes with pharmd
37 episodes with pharmd
34 episodes with pharmd
53 episodes with pharmd
67 episodes with pharmd
22 episodes with pharmd
27 episodes with pharmd
27 episodes with pharmd
19 episodes with pharmd
31 episodes with pharmd
21 episodes with pharmd
15 episodes with pharmd
27 episodes with pharmd
24 episodes with pharmd
49 episodes with pharmd
16 episodes with pharmd
19 episodes with pharmd
16 episodes with pharmd
18 episodes with pharmd
22 episodes with pharmd
33 episodes with pharmd
11 episodes with pharmd
40 episodes with pharmd
32 episodes with pharmd
18 episodes with pharmd
17 episodes with pharmd
13 episodes with pharmd
18 episodes with pharmd
14 episodes with pharmd
53 episodes with pharmd
14 episodes with pharmd
15 episodes with pharmd
12 episodes with pharmd
12 episodes with pharmd
18 episodes with pharmd
18 episodes with pharmd
16 episodes with pharmd
13 episodes with pharmd
16 episodes with pharmd
14 episodes with pharmd
9 episodes with pharmd
40 episodes with pharmd
20 episodes with pharmd
15 episodes with pharmd
8 episodes with pharmd
11 episodes with pharmd
10 episodes with pharmd
11 episodes with pharmd
19 episodes with pharmd
9 episodes with pharmd
19 episodes with pharmd
12 episodes with pharmd
13 episodes with pharmd
14 episodes with pharmd
10 episodes with pharmd
4 episodes with pharmd
20 episodes with pharmd
12 episodes with pharmd
19 episodes with pharmd
22 episodes with pharmd
18 episodes with pharmd
8 episodes with pharmd
6 episodes with pharmd
15 episodes with pharmd
14 episodes with pharmd
8 episodes with pharmd
15 episodes with pharmd
8 episodes with pharmd
6 episodes with pharmd
5 episodes with pharmd
12 episodes with pharmd
12 episodes with pharmd
3 episodes with pharmd
14 episodes with pharmd
8 episodes with pharmd
17 episodes with pharmd
7 episodes with pharmd
6 episodes with pharmd
3 episodes with pharmd
8 episodes with pharmd
6 episodes with pharmd
12 episodes with pharmd
3 episodes with pharmd
7 episodes with pharmd
13 episodes with pharmd
12 episodes with pharmd
6 episodes with pharmd
5 episodes with pharmd
6 episodes with pharmd
9 episodes with pharmd
3 episodes with pharmd
8 episodes with pharmd
5 episodes with pharmd
6 episodes with pharmd
4 episodes with pharmd
4 episodes with pharmd
3 episodes with pharmd
5 episodes with pharmd
5 episodes with pharmd
5 episodes with pharmd
4 episodes with pharmd
9 episodes with pharmd
3 episodes with pharmd
4 episodes with pharmd
6 episodes with pharmd
5 episodes with pharmd
7 episodes with pharmd
4 episodes with pharmd
5 episodes with pharmd
7 episodes with pharmd
6 episodes with pharmd
4 episodes with pharmd
3 episodes with pharmd
7 episodes with pharmd
4 episodes with pharmd
9 episodes with pharmd
10 episodes with pharmd
8 episodes with pharmd
10 episodes with pharmd
8 episodes with pharmd
11 episodes with pharmd
3 episodes with pharmd
4 episodes with pharmd
7 episodes with pharmd
5 episodes with pharmd
2 episodes with pharmd
5 episodes with pharmd
7 episodes with pharmd
2 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
4 episodes with pharmd
4 episodes with pharmd
4 episodes with pharmd
4 episodes with pharmd
6 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
9 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
3 episodes with pharmd
2 episodes with pharmd
3 episodes with pharmd
2 episodes with pharmd
5 episodes with pharmd
In this encore episode of 'Relentlessly Seeking Value,' host Stacey Richter revisits an inspiring conversation with Marilyn Bartlett, a CPA who transformed the State of Montana's employee health plan from a $9 million deficit to a $112 million surplus within three years. Known for her fiscal discipline and patient-first approach, Marilyn shares her strategic steps, from identifying waste in the system and securing quick wins to negotiating better deals with hospitals and ensuring long-term success. She emphasizes the importance of assembling a strong team, maintaining transparency, and staying focused on the ultimate goal of creating real health value. This episode is a must-listen for anyone looking to drive meaningful change in the healthcare industry. === LINKS ===
Tim Ulbrich, PharmD covers 10 practical year-end financial moves to reduce tax burden, build clarity, and start 2026 with confidence—plus a bonus step most people overlook. Episode Summary As 2025 winds down, it's tempting to push financial decisions into January. But some of the most impactful moves you can make happen before the calendar turns. In this episode, YFP Co-Founder & CEO Tim Ulbrich, PharmD walks through 10 practical, foundational financial moves to make before 2026 to help you reduce tax burden, invest with intention, organize your financial life, and enter the new year with clarity and momentum. The episode wraps with a bonus step that isn't on most year-end checklists but may be one of the most leveraged decisions you can make heading into 2026: evaluating whether it's time to hire a financial planner or reassess your current advisory relationship. This is your financial "closing shift" for 2025—simple, intentional moves that quietly build confidence and long-term wealth. What you'll learn in this episode: How to perform a year-end financial inventory and why tracking net worth is one of the most powerful planning habits. Which tax-advantaged accounts need attention before December 31 and how to prioritize last-minute contributions. The importance of rebalancing your investment portfolio and prepare for paycheck changes heading into a new year. Why organizing estate documents, beneficiaries, and a "legacy folder" creates clarity and peace of mind. How to set meaningful financial goals for 2026 and evaluate whether it's time to hire (or reassess) a financial planner. Mentioned on the Show YFP Legacy Folder Checklist
Nuclear pharmacy is rapidly moving from the background to the forefront of oncology care.In this season finale episode, Nic Mastiscusa, PharmD, Chief Nuclear Pharmacist at the University of Iowa Hospitals and Clinics, breaks down how theranostics and radiopharmaceutical therapies are changing the way certain cancers are diagnosed and treated. Nick explains how targeted radioactive drugs can both locate tumors and deliver therapy, what this means for diseases like neuroendocrine tumors and prostate cancer, and why concepts such as alpha vs. beta emitters and dosimetry matter clinically.This episode is ACPE-accredited for pharmacists and pharmacy technicians and is worth 0.5 credit.Learning ObjectivesDescribe the role of nuclear pharmacy and theranostics in oncology careDifferentiate between diagnostic and therapeutic radiopharmaceuticalsExplain clinical differences between alpha- and beta-emitting radiopharmaceuticalsIdentify the role of dosimetry in personalized radiopharmaceutical treatmentRecognize key patient counseling and safety considerations related to radiopharmaceutical therapies CE InformationThis activity is ACPE accredited for pharmacists and pharmacy technicians.CE credit is available upon successful completion of the post-activity requirements.Access the CE activity here:https://www.lecturepanda.com/r/PQIPodcastTheranosticsCE DisclosuresNic Mastascusa, PharmD, R.Ph., BCNP discloses affiliations with NMTCB and NANP.
Quality Corner Show Host Nick Dorich, PharmD, welcomes back Richard Waithe, PharmD, COO of Pyrls, to discuss the integration of Pyrls with EQUIPP Copilot and how this can supercharge clinical pharmacy workflow.This episode focuses on how this powerful combination is helping pharmacists improve patient outreach, enhance consultations, and drive better health outcomes by dramatically improving access to essential drug information.
Melanie Dodd, PharmD, PhC, BCPS, FASHP, is the current President of the American Society of Health-System Pharmacists (ASHP) and the Associate Dean for Clinical Affairs and Professor at the University of New Mexico College of Pharmacy. Dr. Dodd talks through her priorities for ASHP this year, her involvement in the progressive New Mexico Society of Health-System Pharmacists, and her advice to those looking to get involved!
GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing medicine — but at what cost? In this episode of The Exam Room Podcast, host Chuck Carroll sits down with Ben Urich, PharmD, PhD, to break down the real-world data behind the GLP-1 explosion. You'll learn: - How many people are actually using GLP-1 drugs - Why most users stop — and why that's starting to change - The true cost of GLP-1 medications to employers and health plans - Common and serious side effects to be aware of - Why GLP-1s are now being studied for Alzheimer's disease and addiction - What the future holds as more than 30 new drugs enter the pipeline This is a must-watch conversation for anyone considering GLP-1 medications, currently using Ozempic or Wegovy, or wondering where modern weight-loss medicine is headed next.
In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen are joined by Aaron Sutton, LCSW, BCD, CAADC, to explore the unique challenges the holidays can bring when living with diabetes. They share practical strategies and offer guidance on how loved ones can provide meaningful support throughout the holiday season. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Aaron Sutton, LCSW, BCD, CAADC, Director of the Sutton Institute for Psychotherapy Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!
Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.
Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcastCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
Segment 1: The Hidden Lender in America's Drug Supply Chain Guests: Antonio Ciaccia, President, 3 Axis Advisors Alec Ginsberg, Founder, The Drugstore Cowboy Building on Alec Ginsberg's investigative article, “The Hidden Lender in America's Drug Supply Chain,” this discussion exposes how capital flows, credit structures, and opaque financial relationships influence pharmacy viability. Ciaccia and Ginsberg break down what independent pharmacists need to understand about who truly controls leverage in the system—and why transparency matters more than ever. Segment 2: How AI Is Transforming Pharmacy Operations Guests: Harry Travis, BS Pharm, MBA, President, The Travis Group Amanda Awe, PharmD, Clinical Product Consultant, Curatio Advisors Artificial intelligence is no longer theoretical in pharmacy—it's operational. This segment explores how AI is being deployed today to improve workflow efficiency, clinical decision-making, and patient engagement, while addressing the real-world challenges of adoption. Inside the Forces Reshaping America's Drug Supply Chain | TWIRx Thanks to NimbleRx, PRISM by OvaryIT, and Sykes & Company for sponsorsing today's show
Episode Overview: In our inaugural This Week in Pharmacy, we examine the economic, technological, and policy-driven forces transforming pharmacy practice and the U.S. drug supply chain. From hidden financial power structures and AI-enabled operations to federal policy shifts impacting biosimilars, this episode brings together three timely conversations that every pharmacy leader should hear. Segment 1: The Hidden Lender in America's Drug Supply Chain Guests: Antonio Ciaccia, President, 3 Axis Advisors Alec Ginsberg, Founder, The Drugstore Cowboy Building on Alec Ginsberg's investigative article, “The Hidden Lender in America's Drug Supply Chain,” this discussion exposes how capital flows, credit structures, and opaque financial relationships influence pharmacy viability. Ciaccia and Ginsberg break down what independent pharmacists need to understand about who truly controls leverage in the system—and why transparency matters more than ever. Segment 2: How AI Is Transforming Pharmacy Operations Guests: Harry Travis, BS Pharm, MBA, President, The Travis Group Amanda Awe, PharmD, Clinical Product Consultant, Curatio Advisors Artificial intelligence is no longer theoretical in pharmacy—it's operational. This segment explores how AI is being deployed today to improve workflow efficiency, clinical decision-making, and patient engagement, while addressing the real-world challenges of adoption. Segment 3: Policy Watch – IRA, Trump-Era Rx Changes & Biosimilars Guest: Jessica Daley, PharmD In this special policy-focused feature, Dr. Daley unpacks upcoming IRA-related developments and potential Trump-era prescription drug policy changes, with a sharp focus on how they could impact biosimilars and the U.S. supply chain. The conversation highlights what pharmacists should watch closely as regulatory and political pressures continue to evolve. Inside the Forces Reshaping America's Drug Supply Chain | TWIRx Thanks to NimbleRx, PRISM by OvaryIT, and Sykes & Company for sponsorsing today's show
Every day, I hear patients share worries shaped by the growing wave of vaccine misinformation—questions that reveal just how overwhelming today's “infodemic” has become. In this podcast, I explore what vaccine hesitancy really looks like and how pharmacists can use empathy, strong recommendations, and meaningful dialogue to help rebuild confidence in immunization.Presenter:Mary Barna Bridgeman, PharmD, BCPS, BCGPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine Clinical Pharmacy SpecialistRobert Wood Johnson University Hospital-New BrunswickNew Brunswick, New JerseyLink to full program:https://bit.ly/4oHDWZqGet access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This is the 69th episode in my drug pronunciation series. In this episode, I divide Kisunla and donanemab-azbt into syllables, tell you which syllables to emphasize, and share my sources. The written pronunciations are below and in the show notes on https://www.thepharmacistsvoice.com. Special thanks to Megan Hull, PharmD for inspiring me to pick Kisunla for this series. She mentioned it during the CE session she led at the Midyear Meeting of the Ohio Pharmacists Association in Nov 2025. Note: we don't cover pharmacology in this series. Just pronunciations. ⭐️Sign up for The Pharmacist's Voice ® monthly email newsletter! https://bit.ly/3AHJIaF ⭐️ Kisunla = kih-SUHN-lah kih, like kiss SUHN, like sunshine lah, like lullaby Emphasize SUHN Written pronunciation source: Medication Guide for Kisunla on https://kisunla.lilly.com/ (accessed 12-10-25). Spoken pronunciation example: Patient testimonial video https://kisunla.lilly.com/patient-stories (accessed 12-10-25). Donanemab-azbt = doe-NAN-e-mab A-Z-B-T doe, as in a female deer NAN, like the woman's name, Nancy e, which is a short "E" sound or a schwa "E" sound mab, which is the stem (or suffix) for a monoclonal antibody Emphasize NAN Written pronunciation sources: USP Dictionary Online and medlineplus.gov. (accessed 12-10-25) Spoken pronunciation example by Ronald Petersen MD, PhD YouTube video on Mayo Clinic's YouTube Channel (accessed 12-10-25) If you know someone who would like to learn how to say Kisunla and donanemab-azbt, please share this episode with them. Subscribe for all future episodes. This podcast is on all major podcast players and YouTube. Popular links are below. ⬇️ Apple Podcasts https://apple.co/42yqXOG Spotify https://spoti.fi/3qAk3uY Amazon/Audible https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt Host Background: Kim Newlove has been an Ohio pharmacist since 2001 (BS Pharm, Chem Minor). Her experience includes hospital, retail, compounding, and behavioral health. She is also an author, voice actor (medical narrator and audiobook narrator), podcast host, and consultant (audio production and podcasting). Other episodes in this series The Pharmacist's Voice Podcast Episode 358, Pronunciation Series Episode 68 (Journavx) The Pharmacist's Voice Podcast Episode 356, Pronunciation Series Episode 67 (Zanaflex) The Pharmacist's Voice Podcast Episode 352, Pronunciation Series Episode 66 (Yescarta) The Pharmacist's Voice Podcast Episode 350, Pronunciation Series Episode 65 (Xarelto) The Pharmacist's Voice Podcast Episode 349, Pronunciation Series Episode 64 (acetaminophen) The Pharmacist's Voice Podcast Episode 348, Pronunciation Series Episode 63 (Welchol/colesevelam) The Pharmacist's Voice Podcast Episode 346, Pronunciation Series Episode 62 (valacyclovir) The Pharmacist's Voice Podcast Episode 343, Pronunciation Series Episode 61 (ubrogepant) The Pharmacist's Voice Podcast Episode 341, Pronunciation Series Episode 60 (topiramate) The Pharmacist's Voice Podcast Episode 339, Pronunciation Series Episode 59 (Suboxone) The Pharmacist's Voice Podcast Episode 337, Pronunciation Series Episode 58 (rosuvastatin) The Pharmacist's Voice Podcast Episode 335, Pronunciation Series Episode 57 (QVAR) The Pharmacist's Voice Podcast Episode 333, Pronunciation Series Episode 56 (pantoprazole) The Pharmacist's Voice Podcast Episode 330, Pronunciation Series Episode 55 (oxcarbazepine) The Pharmacist's Voice Podcast Episode 328, Pronunciation Series Episode 54 (nalmefene) The Pharmacist's Voice Podcast Episode 326, Pronunciation Series Episode 53 (Myrbetriq) The Pharmacist's Voice Podcast Episode 324, Pronunciation Series Episode 52 (liraglutide) The Pharmacist's Voice Podcast Episode 322, Pronunciation Series Episode 51 (ketamine) The Pharmacist's Voice Podcast Episode 320, Pronunciation Series Episode 50 (Jantoven) The Pharmacist's Voice Podcast Episode 318, Pronunciation Series Episode 49 (ipratropium) The Pharmacist's Voice Podcast Episode 316, Pronunciation Series Episode 48 (hyoscyamine) The Pharmacist's Voice Podcast Episode 313, Pronunciation Series Episode 47 (guaifenesin) The Pharmacist's Voice Podcast Episode 311, Pronunciation Series Episode 46 (fluticasone) The Pharmacist's Voice Podcast Episode 309, Pronunciation Series Episode 45 (empagliflozin) The Pharmacist's Voice Podcast Episode 307, Pronunciation Series Episode 44 (dapagliflozin) The Pharmacist's Voice Podcast Episode 304, Pronunciation Series Episode 43 (cetirizine) The Pharmacist's Voice Podcast Episode 302, Pronunciation Series Episode 42 (buspirone) The Pharmacist's Voice Podcast Episode 301, Pronunciation Series Episode 41 (azithromycin) The Pharmacist's Voice Podcast Episode 298, Pronunciation Series Episode 40 (umeclidinium) The Pharmacist's Voice Podcast Episode 296, Pronunciation Series Episode 39 (Januvia) The Pharmacist's Voice Podcast Episode 294, Pronunciation Series Episode 38 (Yasmin) The Pharmacist's Voice Podcast Episode 292, Pronunciation Series Episode 37 (Xanax, alprazolam) The Pharmacist's Voice Podcast Episode 290, Pronunciation Series Episode 36 (quetiapine) The Pharmacist's Voice Podcast Episode 287, pronunciation series ep 35 (bupropion) The Pharmacist's Voice Podcast Episode 285, pronunciation series ep 34 (fentanyl) The Pharmacist's Voice Podcast Ep 281, Pronunciation Series Ep 33 levothyroxine (Synthroid) The Pharmacist's Voice ® Podcast Ep 278, Pronunciation Series Ep 32 ondansetron (Zofran) The Pharmacist's Voice ® Podcast Episode 276, pronunciation series episode 31 (tocilizumab-aazg) The Pharmacist's Voice ® Podcast Episode 274, pronunciation series episode 30 (citalopram and escitalopram) The Pharmacist's Voice ® Podcast Episode 272, pronunciation series episode 29 (losartan) The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin) The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine) The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec) The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol) The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC) The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide) The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF ✅ LinkedIn Newsletter link https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ Get my FREE eBook and audiobook about podcasting ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Drug pronunciation course https://www.kimnewlove.com ✅ Podcasting course https://www.kimnewlove.com/podcasting ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with my coach, Dave Jackson from The School of Podcasting! *New 12-4-25* Click my affiliate link: https://community.schoolofpodcasting.com/invitation?code=G43D3G Thank you for listening to episode 360 of The Pharmacist's Voice ® Podcast. If you know someone who would like this episode, please share it with them!
Megan Smith, PharmD, joined Over the Counter to discuss continuously updated pneumococcal vaccines and the pharmacist's role among the greater health care community in managing pneumococcal diseases.
The Community Leadership Award is a prestigious award recognizing our community pharmacists and their commitment to their patients. Each year at the Retail Business Conference (RBC), this award is presented to an independent pharmacist who demonstrates a commitment to promoting the principles of community pharmacy. In this episode, Jason Callori speaks with finalist, Mike Burns, PharmD, AuBurn Pharmacies, on his advocacy efforts at the state and national level. Burns also discusses how his community involvements help him and his staff best serve their patients.
In Part 2 of the 2026 pipeline series, host Carolyn Liptak welcomes Dr. Amanda Frick, Senior Clinical Manager, Strategic Clinical Intelligence at Vizient, to explore the advanced therapies pipeline: cell therapies, gene therapies, tissue-engineered products, and combination advanced therapy products. The discussion explores major pipeline trends, six leading products to watch, and the growing innovation expected to shape clinical practice in 2026. Guest speakers: Amanda Frick, PharmD, BCPS Senior Clinical Manager, Strategic Clinical Intelligence Spend Management Vizient Host: Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director Center for Pharmacy Practice Excellence (CPPE) Vizient Show Notes: [00:05] — Introduction Announcer opens the episode. Host Carolyn Liptak introduces the focus on advanced therapies: cell & gene therapies, tissue-engineered products, and combination products. Guest: Dr. Amanda Frick, Senior Clinical Manager, Strategic Clinical Intelligence at Vizient. [01:07] — Defining Advanced Therapies FDA groups cell and gene therapies within advanced therapies. Total FDA-approved advanced therapies: 46. Amanda monitors 29 drug-like therapies within that group. [02:01] — Pipeline Size and Approval Activity S. pipeline: 264 agents in development. About 10 agents approach FDA decision annually. Actual approvals: 5–7 per year on average. [02:56] — Big-Picture Trends in Cell & Gene Therapy Oncology dominates 40–50% of all CGTs in development. Expanding into autoimmune, neurology, and earlier-phase therapies for diabetes, angina, osteoarthritis. Movement toward allogeneic ("off-the-shelf") therapies Designed to overcome limits of autologous cell manufacturing. Reduces wait time and manufacturing failures. Resurgence of therapeutic vaccines Currently 3 approved (Sipuleucel-T, Talimogene, Papzimeos ). 20+ vaccines in the pipeline, largely targeted to cancer. CE program coming Jan 29. [06:13] — Therapy #1: Tabelecleucel or Tab-cel (Allogeneic EBV-Specific T-Cell Therapy) First allogeneic T-cell therapy expected in the U.S. For EBV-positive post-transplant lymphoproliferative disorder (PTLD). “Off-the-shelf” and donor-derived. [07:07] — Clinical Need & Outcomes Currentstandard of care: rituximab. After relapse, survival
The Community Leadership Award is a prestigious award recognizing our community pharmacists and their commitment to their patients. Each year at the Retail Business Conference (RBC), this award is presented to an independent pharmacist who demonstrates a commitment to promoting the principles of community pharmacy. In this episode, Jason Callori speaks with finalist, Mike Burns, PharmD, AuBurn Pharmacies, on his advocacy efforts at the state and national level. Burns also discusses how his community involvements help him and his staff best serve their patients.
Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.
Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
On this episode, we define major depressive disorder (MDD) and describe its clinical presentations, diagnostic criteria, etiologies, and pathophysiology. We also evaluate current guidelines and evidence-based treatment strategies for managing major depression, including pharmacological and nonpharmacological interventions. We then compare and contrast the efficacy, safety profiles, and appropriate use of antidepressant therapies, psychotherapy modalities, and adjunctive treatments in managing depression. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below: www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast.. You can get a copy of HPM at the links below: Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/ If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com
Jennifer Shannon, PharmD shares one of the most inspiring journeys in independent pharmacy. From opening Lily's Pharmacy with no patients, to building a pioneering transitions-of-care program, to fighting PBM patient steering at the state level, Jennifer has pushed for better care at every turn. She walks through how FairRx saved their business, how her community rallied behind her, how her kids supported seniors during COVID, and how she and her husband now run a 39-stall equine farm. It's a story of advocacy, resilience, and redefining what pharmacy can be. This episode also marks a special moment for our team — a heartfelt farewell to Mark Bivins, whose presence, leadership, and passion helped shape so much of what this podcast has become. 00:00 — Jennifer Shannon's Origin Story & Why She Opened Lily's Pharmacy 03:42 — Building a Pharmacy With No Patients: Community, Cupcakes & Persistence 08:55 — The Transitions-of-Care Program That Changed Everything 14:12 — Taking on CVS/Caremark & Testifying Against PBM Abuse 21:40 — The Birth of FairRx and Fighting to Save Their Pharmacy 29:03 — Kids Helping Seniors During COVID: A Community Moment 34:28 — How Jennifer Became an “Accidental” Equine Pharmacist 41:10 — A Heartfelt Farewell to Mark Bivins Hosted By: Mark Bivins Guest: Jennifer Shannon | Owner of Lily's Pharmacy Looking for more information about independent pharmacy? Visit https://www.redsailtechnologies.com
Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn. Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare. 02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone. You can learn more at ICER.org and follow Sarah on LinkedIn. @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl
Tim & Tim discuss how to handle a windfall or inheritance with clarity emotionally, financially, and strategically during the biggest wealth transfer in U.S. history. This episode is brought to you by the American Pharmacists Association (APhA). Episode Summary Handling a windfall or inheritance isn't just about the money—it's an emotional, relational, and identity-level shift. Whether it's an inheritance, equity payout, stock options vesting, or another financial surprise, the "right" next step can feel overwhelming. Many people think the challenge is how to invest a large sum… but the real challenge often begins much earlier: Who am I now that money is no longer the limiting factor? In this episode, Tim Ulbrich, PharmD, and Tim Baker, CFP®, RICP®, RLP® break down how to prepare for, navigate, and thoughtfully plan through sudden wealth. They talk about the emotional side of receiving money, how to avoid rushed decisions, the importance of building the right team, tax considerations, and how to align a windfall with your goals, values, and relationships. With the largest wealth transfer in U.S. history underway, this is a conversation every generation needs to hear. If you've received a windfall, expect one, or simply want to understand how to handle one wisely, this episode will help you slow down, think clearly, and make decisions you won't regret. What you'll learn in this episode: Why sudden wealth creates emotional, identity, and relational shifts—not just financial ones The most common types of windfalls and why they require different planning strategies How to avoid rushed decisions and use a "90-day pause" to regain clarity The key professionals you need on your team before making major moves How taxes, investment priorities, and giving strategies change when a windfall enters the plan Mentioned on the Show Mom and Dad, We Need to Talk by Cameron Huddleston Cerulli Associates "Great Wealth Transfer" data "Die With Zero" by Bill Perkins YFP Episode: 5 Key Questions to Ask Before Hiring a Financial Planner
Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient medical oncology clinical pharmacist at Sylvester Comprehensive Cancer Center, about the importance of engaging the whole multidisciplinary team in biomarker testing for optimal patient outcomes. "I often talk to my gastroenterologist and ask them to get more than 1 biopsy to make sure that we have enough tissue for now and even in the future." - Manish A. Shah, MD, FASCO Instead of lumping all gastric cancers into one group, we use these biomarkers to split them out... We have more refined and tailored treatments for patients with gastroesophageal adenocarcinoma based on these biomarkers." - Manish A. Shah, MD, FASCO "Nurses in the infusion center are a huge help that we absolutely need, and administering this treatment would be very difficult if we didn't have scaled and experienced nurses here." - Aleksandra (Sasha) Watson, PharmD "What I see is just a lot of patients having hope—some new part of their cancer that we can target with a drug that we previously didn't have any options for." - Aleksandra (Sasha) Watson, PharmD Guests: Manish A. Shah, MD, FASCO Director, Gastrointestinal Oncology Program Weill Cornell Medicine New York, NY Aleksandra (Sasha) Watson, PharmD Outpatient Medical Oncology Clinical Pharmacist (GI + Sarcoma) Sylvester Comprehensive Cancer Center Miami, FL Resources ACCC Biomarkers Webpage ACCCBuzz Blog: Importance of Biomarker Testing, Patient Goals and Education When Treating Gastric Cancer
Send us a textDid you know that someone needs blood in the United States every two seconds? Whether it's for surgeries, cancer treatment, traumatic injuries or something else, your blood donation could help save a life. Suzanne Felton, Laboratory manager at St. Luke's, and Adam Wilcox, St. Luke's Clinical Pharmacy manager and a frequent blood donor, join Dr. Arnold to discuss blood donation.If you are interested in donating blood, visit lifeservebloodcenter.org to schedule your donation appointment. Do you have a question about a trending medical topic? Ask Dr. Arnold! Submit your question and it may be answered by Dr. Arnold on the podcast! Submit your questions at: https://www.unitypoint.org/cedarrapids/submit-a-question-for-the-mailbag.aspxIf you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.
In this special Giving Tuesday episode, Ginger talks with Chuck Akanegbu, PharmD, a PGY1 resident and longtime NCODA PSO leader, whose involvement in the student community led to something bigger than he ever expected: donating stem cells through the National Marrow Donor Program (NMDP).Chuck reflects on how the PSO shaped his interest in oncology, what leadership taught him, and how he went from supporting donor drives as a student to becoming a donor himself. He breaks down the donation process in a straightforward way and shares how the experience is shaping his approach as a future oncology pharmacist.It's a timely reminder of what Giving Tuesday represents at NCODA: showing up for others, supporting patients and peers, and taking action when you have the chance to make an impact.Learn more about NMDP here.
Jami Mann, PharmD, MBA, is the Executive Director of Virtual Care Services at UNC Health. Dr. Mann has a pharmacy background - I was fortunate enough to serve as one of her preceptors in residency - and then went outside of pharmacy 5 years ago to lead virtual care for UNC Health. You'll hear about her path along with how virtual care fares in the post-COVID world. It will get your wheels turning as mine did on how we can further our virtual care offerings to expand care overall. We also talk about leadership and how to utilize your skill sets to lead an unchartered area and do it through authenticity. It's an episode you don't want to miss!
Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTGeoff Wall, PharmD, FCCP, BCPSProfessor of Pharmacy PracticeIowa Methodist Medical CenterRachel Maynard and Geoff Wall have no relevant financial relationships to disclose.Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.0.05 CEU/0.5 HrUAN: 0107-0000-25-363-H01-PInitial release date: 12/1/2025Expiration date: 12/1/2026Additional CPE details can be found here.
Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTGeoff Wall, PharmD, FCCP, BCPSProfessor of Pharmacy PracticeIowa Methodist Medical CenterRachel Maynard and Geoff Wall have no relevant financial relationships to disclose. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.0.05 CEU/0.5 HrUAN: 0107-0000-25-363-H01-PInitial release date: 12/1/2025Expiration date: 12/1/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
Listen in as our expert panel discusses critical aspects of managing patients on oral cancer therapies. Our experts review tips for optimizing patient care and share best practices for handling these specialized medications.Special guests:Jill Cassaday, BPharm, PharmD, BCPS, BCOPClinical Pharmacist Specialist – Multiple MyelomaBanner MD Anderson Cancer CenterSamuel Snowaert, PharmD, BCOP, MBAClinical Oncology Pharmacist Pharmacists Optimizing Oncology Care Excellence in Michigan (POEM)Covenant Cancer Care CenterLisa Thompson, PharmD, BCOP, CPPSClinical Pharmacy Specialist in Oncology Kaiser Permanente ColoradoYou'll also hear practical advice from TRC's Editorial Advisory Board member:Craig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in October 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter, or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ: Specialty MedsChart: Guide for Helping Patients Afford Their MedicationsChart: Drug Interactions: Cytochrome P450 (CYP), P-glycoprotein, and MoreToolbox: Medication Adherence StrategiesAlgorithm: Redosing Oral Medications After VomitingUse code mt1025 at checkout for 10% off a new or upgraded subscription.Send us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.
"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.' That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50
The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
ABOUT THIS EPISODE Who is a pharmacist, and how are they involved in the care of neuroendocrine cancer patients? In this episode, Dr. Amanda Cass, a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt Medical Center, explains the unique role pharmacists play—why they're sometimes called “doctor,” how they support patients starting treatments such as cabozantinib and CAPTEM, and practical tips for staying organized, managing side effects, and navigating medication costs. TOP TEN QUESTIONS Getting to Know the Pharmacist1. What exactly does a pharmacist do, and what training do they go through?2. Why are pharmacists sometimes called “doctor,” and how is that different from a physician? 3. What role does a pharmacist play on the cancer care team? 4. How are pharmacists involved in caring for neuroendocrine cancer patients, both directly and behind the scenes?How Pharmacists Support Treatment5. How can a pharmacist help when someone is starting a new treatment for neuroendocrine cancer? Walk us through an example with Cabozantinib: how do you guide patients in understanding it, taking it, and managing side effects?6. Walk us through another example with CAPTEM (capecitabine and temozolomide): how do you guide patients in understanding it, taking it, and managing side effects?Practical Tips for Patients7. What are some simple ways to stay organized, like keeping a medication list or symptom journal? 8. What practical tips do you share with patients about tracking and managing side effects at home?Access and Communication9. Who can patients talk to about medication costs or financial assistance?10. How does someone find a pharmacist to talk to, and is it important to find one with neuroendocrine cancer experience?ABOUT AMANDA CASSDr. Cass is a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center.Dr. Cass's previous research interests included opioid use in non-metastatic cancer patients after curative treatment and albumin effects on oxaliplatin related toxicities. Her current areas of interest are molecular mutations and use of targeted therapies in NSCLC, immunotherapy in SCLC, and global oncology care.Dr. Cass is the preceptor for the Outpatient Thoracic Oncology Rotation.For more information, visit NCF.net/podcast/50For more information, visit NCF.net.
Send us a textSchedule an Rx AssessmentSubscribe to Master The MarginWhat does it really take to start and sustain a successful compounding pharmacy in 2026? In this episode, Scotty Sykes, CPA, CFP®, and Austin Murray sit down with Amy Summers, PharmD, BCSCP and of Restore Health Consulting, to discuss how pharmacy owners can move from idea to implementation when entering the compounding space.We cover:Designing a purpose-built facility for USP standards and your product mixThe mindset shift from dispensing to creating and how to balance quality with patient careMarket analysis, relationships, and niche focus in building a sustainable businessKey trends driving growth, consolidation, and private investment in the compounding industryMore About Our Guest:Amy Summers, PharmD, BCSCP is an independent consultant, specializing in business, operations, quality assurance, and regulatory compliance matters for the pharmaceutical compounding industry. She earned her PharmD degree from the University of California San Francisco and was among the first pharmacists in the nation to earn a Board Certified Sterile Compounding Pharmacist (BCSCP) credential. Dr. Summers has spent her entire career as a pharmacist in various settings centered around non-sterile and sterile compounding. She has formerly served as Director of Operations and Pharmacist in Charge at organizations engaged in compounding and also as Managing Director of a FDA-registered 503B outsourcing facility. With extensive experience in USP standards, accreditation, cGMP, and regulatory compliance, Dr. Summers has also served as an expert witness for matters related to compounding.Stay connected with Amy and Restore Health Consulting: Amy Summers LinkedInRestore Health Consulting WebsiteRestore Health Consulting LinkedInStay connected with us on social media:Facebook: https://www.facebook.com/sykesandcoTwitter: https://twitter.com/OllinSykesLinkedIn: https://www.linkedin.com/company/sykes-&-company-p-a-?trk=tyahScotty Sykes – CPA, CFP® LinkedIn: https://www.linkedin.com/in/scottysykes/More on this topic:Podcast: The Trusted Pharmacist: Advocacy and Building a Resilient PharmacyPodcast: From Counter to Capitol
Listen in as experts Thomas P. Lodise, PharmD, PhD, and George Sakoulas, MD, FIDSA, explore tailored antibiotic strategies for diverse patients with acute bacterial skin and skin structure infections (ABSSSIs). Their insightful discussion focuses on antibiotic developments that followed publication of the IDSA practice guidelines in 2014 and the challenges unique to ABSSSIs, including a lack of determined bacterial etiology for many cases. PresentersThomas P. Lodise, PharmD, PhDProfessorAlbany College of Pharmacy and Health SciencesInfectious Diseases Clinical Pharmacy SpecialistStratton VA Medical CenterAlbany, New YorkGeorge Sakoulas, MD, FIDSAChief, Infectious DiseasesSharp Rees-Stealy Medical GroupAdjunct Professor of PediatricsUniversity of California San Diego School of MedicineSan Diego, CaliforniaLink to full program:https://bit.ly/4oIKwzsGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
On this episode of The Vitamin Professor Podcast, Professor Gene Bruno talks to Meagan Garza, PharmD of BOIRON, USA.This podcast is brought to you in partnership with VRM Media and Nutraland USA, Inc.For more information about our host and guest, please see the below information.boironusa.comhttps://www.linkedin.com/in/meagan-garza-pharmd-747a39189/nutralandusa.comlinkedin.com/in/gene-bruno-ms-mhs-rh-ahg-2ab0508/www.vrmmedia.com@hnvirtual, #hnvirtual, #meagangarza, #genebruno, #thevitaminprofessorFind our podcast on your favorite platform:podcasts.apple.com/us/podcast/the-vitamin-professor-podcast/id1746137375youtube.com/channel/UCxeQ-IuqCRmq0YLc7jQNMKAmusic.amazon.com/podcasts/a8a96593-b93c-48cf-9fe9-2891c4035dad/the-vitamin-professor-podcastiheart.com/podcast/269-the-vitamin-professor-podc-175888136/
Catie Stimmel, PharmD, joined Over the Counter to discuss the importance of patient safety organizations for the greater health care continuum.
Another powerful episode is live here on IVPN-Voice!
If you're wondering which therapies may influence care delivery, budgets, and decision making in 2026, the pipeline offers an early preview and it points to a year defined by innovation. We're seeing new first in class treatments, thoughtful next generation agents, and a biosimilar market where fewer launches are offset by important competitive shifts driven by recent approvals. John Schoen and Heather Pace from the Center for Pharmacy Practice Excellence join Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine and Drug Information and your Verified RX program host to highlight pipeline agents worth watching and discuss what they may mean for care delivery and spend management in the year ahead. Guest speakers: John Schoen, PharmD, BCPS Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence Heather Pace, PharmD Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence Host: Stacy Lauderdale, PharmD, BCPS Associate Vice President Vizient Center for Pharmacy Practice Excellence Show Notes: 01:01 — Episode Scope The focus is non-CGT therapies; CGT pipeline will be covered in Part 2. 01:50 — Therapeutic Areas With the Most Approvals Oncology leads the pipeline. Others include infectious disease, neurology, rare disease, endocrine, hepatology, dermatology, and rheumatology. 02:37 — Biosimilars in 2026: Momentum or Headwinds? Discussion of potential “biosimilar void”—only 10% of expiring biologic patents have biosimilars in development. Emerging role of PBM private-label biosimilars. 03:51 — FDA Draft Guidance on Interchangeability FDA exploring interchangeable designation for all biosimilars. Potential shift away from clinical efficacy studies in favor of analytical comparisons. Guidance still in draft and open for public comment. 05:34 — John's Top Picks for First-in-Class Agents 06:11 — Orviglance First manganese-based, oral MRI contrast agent. Advantages for patients with kidney impairment. Used for liver imaging. 06:20 — Why Non-Gadolinium Matters Lower risk of nephrogenic systemic fibrosis. 06:46 — Tabelecleucel First allogeneic EBV-specific T-cell therapy. For EBV-positive PTLD post-transplant. Could become new standard of care. 07:42 — Tanruprubart First therapy specifically for severe Guillain-Barré Syndrome (GBS). Shows improved outcomes over IVIG and plasma exchange. 08:20 — Comparing to Standard of Care Review of improved real-world data outcomes. 09:03 — Therapies That May Shift Care Delivery 09:32 — Icotrokinra: First oral IL-23 antagonist for plaque psoriasis. 10:00 — Insulin Icodec First once-weekly basal insulin for type 2 diabetes. Resubmitted after safety concerns in type 1 diabetes. 10:59 — Honorable Mentions Camizestrant SERD for ER+/HER2– metastatic breast cancer. Ensitrelvir (COVID-19) Oral option for pre-exposure prophylaxis. Also being evaluated for treatment. Doravirine + Islatravir (HIV) Introduces new NRTTI class. Cefepime + Zidebactam Active against metallo-β-lactamase–producing organisms. 14:05 — Key Biosimilar Launches Omalizumab (Xolair) First biosimilars in asthma/allergy space. Aflibercept (Eylea) High competition expected pending litigation. Pertuzumab (Perjeta) First biosimilar anticipated in oncology. 15:31 — Biosimilars Approved in 2025, Impacting 2026 Ustekinumab (Stelara): first full year of competition Denosumab (Prolia/Xgeva): 10–15 biosimilars expected Eculizumab (Soliris): notable for rare disease market entry 17:17 — John's Closing Thoughts Strong mix of first-in-class advances and next-gen convenience therapies. 17:36 — Heather's Closing Thoughts 2026 will focus on speed and scale after the 2025 biosimilar wave. Pharmacists pivotal in ensuring smooth patient transitions. VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
Today we are bringing you a conversation on the evolving landscape for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) treatment. Ryan Haumschild, PharmD, MS, MBA, vice president of ambulatory pharmacy at Emory Healthcare and Winship Cancer Institute, spoke with Marilyn Glassberg, MD, the John W. Clarke Professor and Chair of medicine at Loyola University Chicago Stritch School of Medicine; Ayodeji Adegunsoye, MD, MSc, PhD, FACP, FCCP, assistant professor at the University of Chicago; and Janet Pope, MD, MPH, professor of medicine and division member of rheumatology at the University of Western Ontario in Canada. IPF and PPF are increasingly prevalent conditions that pose a growing burden on both patients and health care systems. Despite the availability of FDA-approved antifibrotic therapies, the median survival for patients with IPF and PPF remains less than 5 years after diagnosis—underscoring the critical unmet needs that persist in this field. The panelists discussed the impact these conditions have on patients' lives, evaluated emerging agents, and addressed economic considerations that affect treatment decisions and health care resource allocation.
Join Ryan K. Shields, PharmD, MS, in the second of three recap podcasts taken from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients.” Learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:The diverse mechanisms of β-lactam resistanceThe effect of resistance mechanisms on susceptibility to antimicrobials 2024 IDSA guidance for treatmentConsiderations for antibiotic selectionThe role of combination therapyPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:CCO: https://bit.ly/3LXzateProCE: https://bit.ly/3Mjao6GGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join Ryan K. Shields, PharmD, MS, in the third of 3 podcasts from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients” to learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:Mechanisms of resistance in S. maltophiliaCurrent frontline therapies2024 IDSA guidance for treatmentPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:https://bit.ly/3JWaqRvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn Bulloch, PharmD, BCPS, FCCM, speaks with Terry Fulmer, PhD, RN, FAAN, President of the John A. Hartford Foundation, about her Norma J. Shoemaker Honorary Lecture at the 2025 Critical Care Congress and the transformative impact of the 4Ms framework—What Matters, Medication, Mentation, and Mobility—on age-friendly critical care. Dr. Fulmer shares her journey from bedside critical care nurse to national leader in geriatric health, emphasizing the need to adapt healthcare systems to meet the needs of an aging population. She discusses the development of the Age-Friendly Health Systems initiative, a collaboration among the John A. Hartford Foundation, Institute for Healthcare Improvement, American Hospital Association, and Catholic Health Association. Now implemented in nearly 5000 facilities, the initiative is supported by evidence from models such as the Acute Care of the Elderly (ACE) units, Hospital Outcomes Program for Elders (HOPE) initiative, and Nurses Improving Care for Healthsystem Elders (NICHE) program. The episode highlights the January 2025 adoption of a Centers for Medicare and Medicaid Services measure that incorporates the 4Ms into inpatient care standards. Dr. Fulmer explains how hospitals of all sizes can implement age-friendly practices using existing resources and how multiprofessional collaboration is key to success. She also discusses findings from a national survey from Age Wave and the John A. Hartford Foundation, which revealed that only 19% of older adults feel their clinicians consistently address all 4Ms. Listeners will gain insight into how the 4Ms framework improves outcomes and promotes functional recovery in older adults. Whether you're a clinician, educator, or healthcare leader, this episode offers practical strategies and a compelling call to action to join the age-friendly health systems movement.
Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.
Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
Special Guest: Ilisa B.G. Bernstein, PharmD, JD CEO & Co-founder Johny Kello | MatchRX Topic: DSCSA Compliance, Industry Readiness & the Future of Pharmacy Safety Episode Overview This week on TWIRx, Johny Kello welcomes one of the 50 Most Influential People in Pharmacy, Ilisa B.G. Bernstein, PharmD, JD, to break down the current state of DSCSA compliance as the industry approaches the critical November 2025 enforcement deadline. With decades of leadership in pharmacy practice, regulatory policy, and national advocacy, Dr. Bernstein brings unmatched clarity to what pharmacies must do now — and how the right technology partnerships can keep them operational, efficient, and fully compliant. Together, Johny and Dr. Bernstein discuss why DSCSA readiness remains one of the most pressing challenges for independent and community pharmacies — from data verification and product tracing to avoiding shipment rejections, workflow disruptions, and audit exposure. Johny Kello LinkedIn: https://www.linkedin.com/in/johny-kello/ Ilisa B.G. Bernstein, PharmD, JD LinkedIn: https://www.linkedin.com/in/ilisa-bernstein-b67222174/ Learn more: https://www.matchrx.com/ Featured guest: Dr. Jordyn Nordé, PharmD, MBA, is a forward-thinking clinical pharmacist and community leader based in St. Louis who combines advanced clinical training with business acumen to drive impact in underserved populations. With experience in ambulatory care and medication management for conditions like hypertension, diabetes and pain, she is also the founder of an initiative bringing minority pharmacy professionals together through mentorship, entrepreneurship and wellness conversations. Her dual credentials enable her to bridge healthcare, professional development and advocacy — positioning her as an emerging influencer in pharmacy practice transformation. LinkedIn: https://www.linkedin.com/in/jordynnorde/
In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.
Hi and welcome to How Humans Heal. I'm Dr. Doni Wilson, and in today's episode I'm talking with Dr. Nayan Patel. He's a PharmD (a pharmacist) and owns two compounding pharmacies. Dr. Patel is also the author of "The Glutathione Revolution: Fight Disease, Slow Aging, and Increase Energy." He does incredible work in product development and research at Auro Wellness, and he's here to share that knowledge with us. As a pharmacist, Dr. Patel has a wealth of wisdom and decades of experience. Dr. Patel has been a pharmacist for about eight years now, and before that he worked in a compounding pharmacy since 1993. Dr. Patel's interest in glutathione started from working in a compounding pharmacy where glutathione was the solution for many patients. Glutathione is that thing that takes work away from your body. It's an antioxidant. It's a massive detoxifier. It helps the liver detoxify chemicals. Once you do that, the body frees up, and when it frees up, it starts healing, rejuvenating, regenerating. It's a multitasker, a multi-tool antioxidant. Even applying glutathione on your arms, it circulates around your whole body and eventually gets to all your cells. I love this conversation with Dr. Patel because he's found a way to support our bodies to recover from stress and toxin exposure using glutathione, our most powerful antioxidant. So check out today's conversation! We're here to help you! LINKS FROM THE EPISODE: Connect with Dr. Patel: https://aurowellness.com/doctordoni Sign Up For Your 14-Day Detox: https://doctordoni.com/detox-program Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI: Quick links to social media, free guides and programs, and more: https://doctordoni.com/links Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.
He was told to expect paralysis or death. Instead, he reclaimed his life. In this episode of Vitality Made Simple, Jason Barrett, PharmD joins us to share his story through years of crippling pain and an autoimmune diagnosis that left him fearing paralysis or death. He explains how discovering hidden food sensitivities, changing his diet, addressing oral infections, and simplifying his lifestyle helped him reclaim his vitality and bring real hope to others stuck in the chronic illness spiral.Visit my website DrDebbieOzment.com for valuable free downloads. Additionally, you will find shopping links which I have curated on the website. Please follow me on instagram at drdebbieozment.
In this episode, Eric Huckins discusses trends shaping specialty pharmacy, from managing high-cost infusions and direct-to-consumer models to preparing for the Inflation Reduction Act. He shares how Lumicera is partnering with health systems to enhance efficiency, integration, and patient care.This episode is sponsored by Lumicera Health Services.
On this episode, we define osteoporosis and describe its clinical presentations, underlying pathophysiology, and common etiologies. We compare and contrast the efficacy, safety profiles, and appropriate use of various antiresorptive and anabolic agents used in osteoporosis management. We also review current guidelines and evidence-based approaches for the prevention and treatment of osteoporosis, including pharmacological and nonpharmacological interventions. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below: www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast.. You can get a copy of HPM at the links below: Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/ If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com
© 2020-2025 Ivy Podcast Discovery LLC
